SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve™ Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients’ coronary vessel to de novo state. A real-time presentation of this revolutionary technology was successfully demonstrated at the 23rd Annual Transcatheter Therapeutics (TCT) Conference held in San Francisco.
